Skip to main content
. 2022 Mar 25;9:826537. doi: 10.3389/fmed.2022.826537

Figure 1.

Figure 1

Antibody response after two doses of SARS-CoV-2 vaccine in MPN patients and HCs. MPN, myeloproliferative neoplasms; Anti-S Ab, anti-spike-receptor binding domain antibody; MPN-Ruxo, MPN with ruxolitinib; MPN-no Ruxo, MPN without ruxolitinib; HCs, healthy controls; SARS-CoV-2, severe acute respiratory coronavirus 2.